Skip to main content

Hyaluronidase / Ocrelizumab Dosage

Medically reviewed by Drugs.com. Last updated on Nov 5, 2024.

Applies to the following strengths: ocsq 23,000 units-920 mg /23 mL

Usual Adult Dose for Multiple Sclerosis

23 mL (920 mg ocrelizumab and 23,000 units hyaluronidase) subcutaneously over approximately 10 minutes every 6 months

Comments:


Uses:

Renal Dose Adjustments

Mild Renal Dysfunction: No adjustment recommended.
Moderate and Severe Renal Dysfunction: Data not available

Liver Dose Adjustments

Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available

Precautions

US FDA requires a medication guide to assure safe use. For additional information go to: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Assessments prior to the first dose:

Premedication:

Storage requirements:

Preparation and administration techniques:

General:

Monitoring:

Patient advice:

More about hyaluronidase / ocrelizumab

Patient resources

Other brands

Ocrevus Zunovo

Professional resources

Other brands

Ocrevus Zunovo

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.